Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (first-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
| Treanda (in combination with rituximab) | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia | Withdrawn | |||
| Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Active | ||
| Trelegy Ellipta | fluticasone furoate umeclidinium vilanterol | Chronic obstructive pulmonary disease (COPD) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trelegy Ellipta | fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | Asthma, maintenance | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete | ||
| Tremfya | guselkumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tremfya | guselkumab | Psoriatic arthritis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 20, 2024